Insurers and Medicaid evaluate medical necessity based on a formal standard to determine if Applied Behavior Analysis (ABA) therapy is reasonable, effective, and required for a patient’s condition.

The determination of medical necessity for ABA therapy typically hinges on three core criteria:

• Formal Diagnosis: The child must have a documented diagnosis of autism spectrum disorder (ASD) according to the DSM-5, provided by a licensed healthcare professional (such as a psychologist or developmental pediatrician).
• Functional Impairment: There must be objective evidence that the child faces meaningful challenges in communication, social interaction, or adaptive behavior that significantly impact safety, learning, or daily family life.
• Expectation of Improvement: The individualized treatment plan must demonstrate that ABA therapy is likely to help the child build skills or reduce problematic behaviors, showing a reasonable expectation of meaningful progress.

To prove these criteria, insurers require specific documentation, including a Diagnostic Report (often including ADOS results), a Functional Behavior Assessment (FBA) providing baseline data, and a Letter of Medical Necessity (LMN) that synthesizes the clinical rationale for treatment. Clinical guidelines from the NIH and the US Surgeon General further support these criteria by recognizing ABA as an evidence-based, non-experimental treatment for autism.